IMFINZI APPROVED IN THE US AS FIRST AND ONLY PERIOPERATIVE IMMUNOTHERAPY FOR PATIENTS WITH EARLY GASTRIC AND GASTROESOPHAGEAL CANCERS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.